1. The Genomic Alterations of 5α-Reductases and Their Inhibitor Finasteride’s Effect in Bladder Cancer
- Author
-
Chi-Ping Huang, Chih-Rong Shyr, Yi-Tung Tsai, Chi-Cheng Chen, and Teng-Fu Hseih
- Subjects
Male ,Cancer Research ,Cell Survival ,medicine.drug_class ,Population ,030232 urology & nephrology ,Kaplan-Meier Estimate ,03 medical and health sciences ,chemistry.chemical_compound ,5-alpha Reductase Inhibitors ,0302 clinical medicine ,3-Oxo-5-alpha-Steroid 4-Dehydrogenase ,Cell Line, Tumor ,medicine ,Humans ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,Bladder cancer ,Cell growth ,business.industry ,Finasteride ,fungi ,Cancer ,Genomics ,General Medicine ,Middle Aged ,medicine.disease ,Androgen ,Logistic Models ,Urinary Bladder Neoplasms ,Oncology ,chemistry ,Case-Control Studies ,030220 oncology & carcinogenesis ,Dihydrotestosterone ,Cancer research ,Female ,Xtt assay ,business ,medicine.drug - Abstract
Background/aim Since androgens affect urothelial bladder cancer (UBC), we examined whether 5α-reductases (5-AR) have genomic alterations in UBC and whether 5α-reductase inhibitors (5-ARI) affect UBC. Materials and methods The cBioPortal was used to analyze genomic alternations of 5-ARs in UBC cancer genomic datasets. Next, we used the Taiwan National Health Insurance Research database to conduct a population-based case-control study to investigate the effect of a 5-ARI, finasteride on UBC incidence. We also performed an XTT assay to examine the direct effect of finasteride on UBC cells. Results We found that 5-AR genomic alternations were observed in 29% of UBC patients and patients with alternations had shorter disease-free survival. Also, the use of finasteride with >180 cDDDs reduced the risk of UBC. Finasteride could directly inhibit UBC cell growth. Conclusion Based on our findings, we concluded that 5-AR could be explored as a therapeutic target for UBC with 5-ARIs.
- Published
- 2017
- Full Text
- View/download PDF